Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ascletis Pharma, Inc. ( (HK:1672) ) just unveiled an announcement.
Ascletis Pharma Inc. has amended and adopted new terms of reference for its Nomination Committee, emphasizing the importance of diversity and transparency in board appointments. This move is aimed at enhancing the company’s governance structure, potentially impacting its operational efficiency and stakeholder trust.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on developing innovative drugs and treatments, with a market emphasis on addressing significant medical needs.
Average Trading Volume: 6,499,154
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.01B
For an in-depth examination of 1672 stock, go to TipRanks’ Overview page.